Cargando…

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

BACKGROUND: We aimed to characterize etanercept (ETN) use in juvenile idiopathic arthritis (JIA) patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. METHODS: The CARRA Registry is a convenience cohort of patients with paediatric onset rheumatic diseases,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beukelman, Timothy, Lougee, Aimee, Matsouaka, Roland A., Collier, David, Rumsey, Dax G., Schenfeld, Jennifer, Stryker, Scott, Twilt, Marinka, Kimura, Yukiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380401/ https://www.ncbi.nlm.nih.gov/pubmed/34419107 http://dx.doi.org/10.1186/s12969-021-00625-y

Ejemplares similares

Investigation of Inactive Disease States Among Patients With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Mannion, Melissa L., et al.
Publicado: (2022)

Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry
por: Correll, Colleen K, et al.
Publicado: (2023)

Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
por: Beukelman, Timothy, et al.
Publicado: (2022)

The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months
por: Beukelman, Timothy, et al.
Publicado: (2017)

Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
por: Kimura, Yukiko, et al.
Publicado: (2017)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Henderson, Lauren A., et al.
Publicado: (2016)

Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
por: Prahalad, Sampath, et al.
Publicado: (2016)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Wu, Eveline Y., et al.
Publicado: (2019)

Access to Care and Diagnostic Delays in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Neely, Jessica, et al.
Publicado: (2021)

Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry
por: Neely, Jessica, et al.
Publicado: (2022)

Long term functional outcome and quality of life of patients with refractory juvenile idiopathic arthritis treated with etanercept: results of the dutch arthritis and biologicals in children register
por: Anink, Janneke, et al.
Publicado: (2014)

Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
por: Kimura, Yukiko, et al.
Publicado: (2021)

Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey
por: Shenoi, Susan, et al.
Publicado: (2019)

Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Weiss, Jenifer E., et al.
Publicado: (2019)

Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry
por: Tory, Heather, et al.
Publicado: (2020)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Evaluation of an nhs juvenile idiopathic arthritis (JIA) treatment pathway compared to published international recommendations
por: Green, Katherone L, et al.
Publicado: (2014)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

Correction to: Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Weiss, Jennifer E., et al.
Publicado: (2020)

Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus
por: Ota, Sylvia, et al.
Publicado: (2008)

The childhood arthritis & rheumatology research alliance network registry: demographics and characteristics of the initial 6-month cohort
por: Natter, Marc D, et al.
Publicado: (2012)

Association of Race and Ethnicity With Medication Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Roberts, Jordan E., et al.
Publicado: (2022)

Evaluating key performance indicators of the process of care in juvenile idiopathic arthritis
por: Cooper, Sarah M., et al.
Publicado: (2023)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Davies, Rebecca, et al.
Publicado: (2015)

Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease
por: Kim, Susan, et al.
Publicado: (2017)

Disease characteristics and medication use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): preliminary analyses from the CARRAnet registry
por: Ringold, Sarah, et al.
Publicado: (2012)

Treatment advances in systemic juvenile idiopathic arthritis
por: Beukelman, Timothy
Publicado: (2014)

Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
por: Accortt, Neil A., et al.
Publicado: (2017)

Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America
por: Spencer, CH, et al.
Publicado: (2017)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

Joint cartilage thickness and automated determination of bone age and bone health in juvenile idiopathic arthritis
por: Twilt, Marinka, et al.
Publicado: (2017)

Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance
por: Sherman, Matthew A., et al.
Publicado: (2023)

Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
por: Sara, De Sanctis, et al.
Publicado: (2011)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6fel8ihmp4jg3g2g9om1vulab5